Brexucabtagene Autoleucel's Impact on MCL Treatment Landscape: Luhua Wang, MD

This content originally appeared on our sister site, Targeted Oncology.

Brexucabtagene autoleucel (Tecartus), a chimeric antigen receptor (CAR) T-cell therapy, was approved for the treatment of mantle cell lymphoma (MCL) in July 2020. Luhua (Michael) Wang, MD, professor, Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer, discussed the impact that this approval has had on the treatment landscape.

Wang lauded the approvacl and its positive impact. Over 30 patients have been treated with the agent at MD Anderson and that number is growing, he said.

Currently, more and more centers are beginning to use the agent, adding to real-world efficacy and experience data. According to Wang, this approval has been exciting for patients and their families, as it can lead to long-term remission in advanced MCL.

Transcription:

0:08 | I remember very clearly the day when the FDA approved brexucabtagene autoleucel on July 24, of 2020. And after that, we have been using this therapy to save patients’ lives ever since. There is a very intense usage of this product and to the benefit of our patients. So, there is widespread use. We have treated over 30 patients since everything, and given the hospitals have increasing numbers every week, every month. So, we actually are summarizing our real-world data with brexucabtagene autoleucel in the abstract, in an ongoing project with multiple institutions such as the Mayo Clinic, the Moffitt Cancer Center and many other centers. Each use brexucabtagene autoleucel and is ever increasing daily. And we will have much more real-world experience with this. So, this is a really exciting time for our patients and for their families. This therapy could cause long-term remission even in advanced MCL stages.